# Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

> **NCT01445795** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 50 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** 200 mg INX-08189 Fasted
- **DRUG:** Placebo QD Fasted
- **DRUG:** 100 mg INX-08189 QD
- **DRUG:** Placebo QD
- **DRUG:** 100 mg INX-08189 with low-fat meal
- **DRUG:** Placebo with low-fat meal
- **DRUG:** 100 mg INX-08189 BID Fasted
- **DRUG:** Placebo BID Fasted
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01445795
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445795, "Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01445795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*